

Date: August 13, 2025

To,  
BSE Limited,  
20th Floor, P.J. Towers,  
Dalal Street,  
Mumbai - 400001.  
BSE Scrip Code: 544449

National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai – 400 051  
NSE Scrip Symbol: ANTHEM

**Subject:** Outcome of Board Meeting held on Wednesday, August 13, 2025

Dear Sir/Ma'am

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), we would like to inform you that the Board of Directors of Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited) ("Company") at their meeting held on Wednesday, August 13, 2025 which commenced at 04:00 p.m. and concluded at 06:00 p.m. have inter-alia, approved the following matters:

### **1. Unaudited Financial Results**

The Board of Directors (*Board*) have approved the Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of Statutory Auditors for the quarter ended June 30, 2025. The said financials results for the quarter ended June 30, 2025 were duly reviewed and recommended by Audit Committee at its meeting held on August 12, 2025 to the Board.

A copy of the said Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Statutory Auditors are enclosed herewith and the extract of the results will be published in the newspapers as required under Regulation 47 of SEBI LODR Regulations.

### **2. Change in designation of Mr. Ravi Kalla as Chief Information Officer, classified as Senior Management Personnel (SMP)**

Pursuant to Regulation 30 read with Schedule III of the SEBI LODR Regulations, we hereby inform that the Board of Directors on the recommendation of the Nomination & Remuneration Committee at its meeting held on August 12, 2025 approves the re-designation of Mr. Ravi Kalla, Senior General Manager – Information Technology as Chief Information Officer of the Company, classified as Senior Management Personnel as defined under Regulation 16(d) of SEBI LODR Regulations.

The details as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is provided below:

Sr No.	Particulars	Details
1	Name of SMP	Mr. Ravi Kalla
2	Reason for change viz. <del>appointment, re-appointment, resignation, removal, death or</del> otherwise;	<p>The Board of Directors, upon the recommendation of the Nomination and Remuneration Committee, approved the change in designation of Mr. Ravi Kalla from Senior General Manager – Information Technology to Chief Information Officer of the Company classifying as SMP.</p> <p>Mr. Ravi brings in 25 years of experience in information technology, process automation, cyber security, GxP systems (QMS, DMS, LIMS and LMS), with the last two decades in pharmaceutical operations. He has been associated with Anthem since inception.</p> <p>This change in designation is in recognition of his exemplary leadership and significant contributions to the Company's technology initiatives over the past 17 years.</p>
3	i. Date of appointment/re-appointment/cessation (as applicable) & ii. Term of appointment/re-appointment;	i. Not Applicable ii. Not Applicable <i><b>Note:</b> The Change in designation of Mr. Ravi Kalla to Chief Information Officer will be effective from August 13, 2025</i>
4	Brief profile (in case of appointment);	Not Applicable
5	Disclosure of relationships between directors (in case of appointment of a director)	

The above intimation is also be available on the Company's website at <https://www.anthembio.com/investor.html>.

We request you to kindly take the same on record.

Thanking you,

Yours truly,

For Anthem Biosciences Limited

(Formerly known as Anthem Biosciences Private Limited)

---

**Divya Prasad**

**Company Secretary & Compliance Officer**

**Membership No: A41438**

K. P. RAO  
H.N. ANIL  
MOHAN R LAVI

K. VISWANATH  
S. PRASHANTH  
P. RAVINDRANATH

Phone : 080 - 25587385 / 25586814  
Fax : 080 - 25594661  
E-mail : info@kprao.co.in

**Independent Auditor's Review Report on the quarterly Unaudited Standalone Financial results of Anthem Biosciences Limited pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**Review report to  
The Board of Directors of  
Anthem Biosciences Limited  
Bangalore**

1. We have reviewed the Unaudited Standalone Financial result of Anthem Biosciences Limited (the "Company"), for the quarter ended June 30, 2025 included in the accompanying "Statement of Unaudited Consolidated and Standalone Financial results for the quarter ended June 30, 2025 (the Statement) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (Listing Regulations).
2. The Company's management is responsible for the preparation of the Statement, in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India ("ICAI"). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



**Branches**

**Hyderabad** : 3rd Floor, D1, 6-3-652, Kautilya, Somajiguda, Hyderabad - 500 082. Ph.: 040-23322310

**Mysore** : 74, 2nd Main, First Stage, Vijayanagar, Mysore - 570 017. Ph.: 0821-4271908

**Chennai** : Flat 2-A, Second Floor, Shruthi 3/7, 8th Cross Street, Shastrinagar, Adayar, Chennai - 600 020. Ph.: 044- 24903137 / 45511564

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For K. P. Rao & Co.,**  
Chartered Accountants  
FRN: 003135S



**Mohan R Lavi**  
Partner  
Membership No. 029340

**Place: Bangalore**  
**Date: 13<sup>th</sup> August, 2025**

**UDIN: 25029340BMKTKZ5833**

**ANTHEM BIOSCIENCES LIMITED**  
**CORPORATE IDENTITY NUMBER: U24233KA2006PLC039703**

REGISTERED AND CORPORATE OFFICE: NO 49, F1&F2, CANARA BANK ROAD, BOMMASANDRA INDUSTRIAL AREA, PHASE-I, BOMMASANDRA,  
BANGALORE-560099, KARNATAKA INDIA.

Email : investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com

**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE THREE MONTHS ENDED JUNE 30, 2025**

Particulars	Quarter ended			Rs.in Mn
	30/06/2025	31/03/2025	30/06/2024	Year End
	Unaudited	Audited (Note 6)	Unaudited (Note 4)	31/03/2025 Audited
<b>Income:</b>				
Revenue from operations	5,380.11	4,789.84	3,385.39	18,406.49
Other income	277.28	378.19	194.55	1,094.40
<b>Total income</b>	<b>5,657.39</b>	<b>5,168.03</b>	<b>3,579.94</b>	<b>19,500.89</b>
<b>Expenses:</b>				
Cost of materials consumed	1,623.95	1,822.68	1,682.00	8,280.79
Changes in inventories of finished goods, work-in-progress	686.72	(67.18)	(219.37)	(867.05)
Employee benefit expenses	685.69	564.26	465.36	2,521.67
Finance cost	16.06	21.03	26.40	90.89
Depreciation and amortisation expense	226.12	209.89	183.38	779.37
Other expenses	429.46	488.97	225.11	1,580.97
<b>Total expenses</b>	<b>3,668.01</b>	<b>3,039.64</b>	<b>2,362.88</b>	<b>12,386.66</b>
<b>Profit before exceptional items and tax</b>	<b>1,989.38</b>	<b>2,128.39</b>	<b>1,217.06</b>	<b>7,114.23</b>
Exceptional items	-	-	-	-
<b>Profit before tax</b>	<b>1,989.38</b>	<b>2,128.39</b>	<b>1,217.06</b>	<b>7,114.23</b>
<b>Tax expense</b>				
Current tax	500.69	565.43	306.31	1,820.27
Deferred tax	5.29	337.32	57.39	232.08
<b>Total tax expenses</b>	<b>505.98</b>	<b>902.76</b>	<b>363.70</b>	<b>2,052.36</b>
<b>Profit for the Period/Year</b>	<b>1,483.40</b>	<b>1,225.63</b>	<b>853.36</b>	<b>5,061.88</b>
<b>Other comprehensive income</b>				
Other comprehensive income/(loss) not to be reclassified to profit or loss in subsequent period	20.08	2.06	(2.51)	(5.30)
Income tax on above	(5.05)	(0.52)	0.63	1.33
<b>Other comprehensive income/(loss) for the period/year</b>	<b>15.03</b>	<b>1.54</b>	<b>(1.88)</b>	<b>(3.96)</b>
<b>Total comprehensive income for the period/year</b>	<b>1,498.43</b>	<b>1,227.17</b>	<b>851.47</b>	<b>5,057.91</b>
<b>Paid-up equity share capital (Face value of Rs.2 each)</b>	<b>1,123.22</b>	<b>1,118.15</b>	<b>1,118.15</b>	<b>1,118.15</b>
<b>Other Equity</b>				<b>23,613.97</b>
<b>Earnings per share (EPS)</b>	Not Annualised	Not Annualised	Not Annualised	Annualised
Basic	2.65	2.19	1.53	9.05
Diluted	2.64	2.18	1.53	9.01

See accompanying notes to financial results

**Notes:**

1. These unaudited standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 ("the Regulations").
2. The above statement of unaudited standalone financial results ("the Statements") of the Company for the quarter ended June 30, 2025 have been reviewed by the Audit Committee held on August 12, 2025 and approved by the Board of Directors of the Company at the meetings held on August 13, 2025. These statements have been subjected to review by the Statutory Auditor of the Company.
3. The Company has completed its IPO of Offer for Sale equity shares of face value of Rs. 2/- each at an issue price of Rs. 570/- per equity share, comprising offer for sale of 59,575,319 shares by selling share holders. The equity shares of the company were listed on NSE Limited and BSE Limited on July 21, 2025.
4. On July 21, 2025, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE). Accordingly, these are the first quarter results after the listing of the shares and consequently, comparative numbers for the quarter ended June 30, 2024 were not subjected to a review by statutory auditors of the Company and are prepared by the management of the Company, reviewed by the Audit Committee and approved by the Board of Directors of the Company.
5. During the quarter, the company has allotted 2,532,951 nos of fully paid up equity shares of Rs.2 each under "ESOP Scheme 2024" on approval accorded by the Board of Directors of the company at their meetings held on June 11, 2025.
6. Further the figures for the quarter ended March 31, 2025 are the balancing figures between the audited standalone figures of the full financial year ended March 31, 2025 and unaudited standalone year to date figures for the nine months ended December 31, 2024. As stated in note 4 above, these are first quarter results after the listing of the shares and consequently, unaudited standalone year to date figures for the nine months ended December 31, 2024 were not subjected to a review by statutory auditors of the Company and are prepared by the management of the Company, reviewed by the Audit Committee and approved by the Board of Directors of the Company.
7. Prior period/year figures have been reclassified wherever required to confirm to the classification of the current period/year.

**For and on behalf of the board of directors of  
Anthem Biosciences Limited**



**Ajay Bhardwaj**  
Managing Director  
DIN:00333704



Place: Bangalore  
Date: August 13, 2025

K. P. RAO  
H.N. ANIL  
MOHAN R LAVI

K. VISWANATH  
S. PRASHANTH  
P. RAVINDRANATH

Phone : 080 - 25587385 / 25586814  
Fax : 080 - 25594661  
E-mail : info@kprao.co.in

**Independent Auditor's Review Report on the quarterly Unaudited Consolidated Financial Results of Anthem Biosciences Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**Review report to  
The Board of Directors of  
Anthem Biosciences Limited  
Bangalore**

1. We have reviewed the Unaudited Consolidated Financial Results of Anthem Biosciences Limited (the "Company") and its subsidiary (the Company and its subsidiary together referred to as "the Group"), for the quarter ended June 30, 2025 included in the accompanying "Statement of Unaudited Consolidated and Standalone Financial results for the quarter ended June 30, 2025, (the Statement) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (Listing Regulations).
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India ("ICAI"). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.  
We also performed procedures in accordance with the Circulars issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, as amended to the extent applicable.  
The Statement includes the results of the entities mentioned in Annexure 1 to the Statement.
4. The Statement includes the unaudited financial results of one subsidiary, whose financial statements reflect total revenue (before consolidation adjustments) of Rs. 66.58 million and total net loss (before consolidation adjustments) of Rs. 125.50 million and total comprehensive loss (net) of Rs. 125.25 million for the quarter ended on that date, as considered in the Statement, which have been reviewed by us.

**Branches**

**Hyderabad :** 3rd Floor, D1, 6-3-652, Kautilya, Somajiguda, Hyderabad - 500 082. Ph.: 040-23322310


**Mysore :** 74, 2nd Main, First Stage, Vijayanagar, Mysore - 570 017. Ph.: 0821-4271908

**Chennai :** Flat 2-A, Second Floor, Shruthi 3/7, 8th Cross Street, Shastrinagar, Adayar, Chennai - 600 020. Ph.: 044- 24903137 / 45511564



5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For K. P. Rao & Co.,**  
Chartered Accountants  
FRN: 003135S



**Mohan R Lavi**  
Partner  
Membership No. 029340

**Place: Bangalore**  
**Date: 13<sup>th</sup> August, 2025**

**UDIN: 25029340BMKTKY9894**

**Annexure-1**

1. Neoanthem Lifesciences Private Limited



**ANTHEM BIOSCIENCES LIMITED**  
**CORPORATE IDENTITY NUMBER: U24233KA2006PLC039703**

REGISTERED AND CORPORATE OFFICE: NO 49, F1&F2, CANARA BANK ROAD, BOMMASANDRA INDUSTRIAL AREA, PHASE-I, BOMMASANDRA,  
Email : investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com

**STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED JUNE 30, 2025**

Particulars	Quarter ended			Rs in Mn
	30/06/2025	31/03/2025	30/06/2024	Year End
	Unaudited	Audited (Note 6)	Unaudited (Note 4)	Audited
<b>Income:</b>				
Revenue from operations	5,402.09	4,831.97	3,385.94	18,445.53
Other income	228.12	140.62	194.55	857.32
<b>Total income</b>	<b>5,630.21</b>	<b>4,972.59</b>	<b>3,580.49</b>	<b>19,302.85</b>
<b>Expenses:</b>				
Cost of materials consumed	1,622.05	1,835.64	1,684.54	8,306.17
Changes in inventories of finished goods, work-in-progress	686.72	(67.18)	(219.37)	(867.05)
Employee benefit expenses	720.32	597.78	474.60	2,604.94
Finance cost	16.10	5.21	37.05	103.29
Depreciation and amortisation expense	264.46	304.22	186.78	893.71
Other expenses	458.08	513.80	237.13	1,693.11
<b>Total expenses</b>	<b>3,767.73</b>	<b>3,189.47</b>	<b>2,400.73</b>	<b>12,734.17</b>
<b>Profit before exceptional items and tax</b>				
Exceptional items	-	-	-	-
<b>Profit before tax</b>	<b>1,862.48</b>	<b>1,783.11</b>	<b>1,179.76</b>	<b>6,568.68</b>
<b>Tax expense</b>				
Current tax	500.69	615.84	306.31	1,820.27
Deferred tax	3.89	341.05	49.66	235.81
<b>Total tax expenses</b>	<b>504.58</b>	<b>956.89</b>	<b>355.97</b>	<b>2,056.08</b>
<b>Profit for the Period/Year</b>	<b>1,357.91</b>	<b>826.22</b>	<b>823.79</b>	<b>4,512.59</b>
<b>Other comprehensive income</b>				
Other comprehensive income/(loss) not to be reclassified to profit or loss in subsequent period	20.4	2.06	(2.51)	(5.30)
Income tax on above	(5.13)	(0.52)	0.63	1.33
<b>Other comprehensive income/(loss) for the period/year</b>	<b>15.27</b>	<b>1.54</b>	<b>(1.88)</b>	<b>(3.96)</b>
<b>Total comprehensive income for the period/year</b>	<b>1,373.18</b>	<b>827.76</b>	<b>821.91</b>	<b>4,508.63</b>
<b>Paid-up equity share capital (face value of Rs.2 each)</b>	<b>1123.22</b>	<b>1,118.15</b>	<b>1,118.15</b>	<b>1,118.15</b>
<b>Other Equity</b>				<b>22,980.48</b>
<b>Earnings per share (EPS)</b>	Not Annualised	Not Annualised	Not Annualised	Annualised
Basic	2.43	1.48	1.47	8.07
Diluted	2.42	1.47	1.47	8.04

See accompanying notes to financial results

**Notes:**

1. These unaudited consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 ("the Regulations").

2. The above statement of unaudited consolidated financial results ("the Statements") of the Company for the quarter ended June 30, 2025 have been reviewed by the Audit Committee held on August 12, 2025 and approved by the Board of Directors of the Company at the meetings held on August 13, 2025. These statements have been subjected to review by the Statutory Auditor of the Company. The reports of the Statutory Auditor are unqualified.

3. The Company has completed its IPO of Offer for Sale of equity shares of face value of Rs. 2/- each at an issue price of Rs. 570/- per equity share, comprising offer for sale of 59,575,319 shares by selling share holders. The equity shares of the company were listed on NSE Limited and BSE Limited on July 21, 2025.

4. On July 21, 2025 the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE). Accordingly, these are the first quarter results after the listing of the shares and consequently, comparative numbers for the quarter ended June 30, 2024 were not subjected to a review by statutory auditors of the Company and are prepared by the management of the Company, reviewed by the Audit Committee and approved by the Board of Directors of the Company.

5. During the quarter, the company has allotted 2,532,951 nos of fully paid up equity shares of Rs.2 each under "ESOP Scheme 2024" on approval accorded by the Board of Directors of the company at their meetings held on June 11, 2025.

6. Further the figures for the quarter ended March 31, 2025 are the balancing figures between the audited consolidated figures of the full financial year ended March 31, 2025 and unaudited consolidated year to date figures for the nine months ended December 31, 2024. As stated in note 4 above, these are first quarter results after the listing of the shares and consequently, unaudited consolidated year to date figures for the nine months ended December 31, 2024 were not subjected to a review by statutory auditors of the Company and are prepared by the management of the Company, reviewed by the Audit Committee and approved by the Board of Directors of the Company.

7. The consolidated financial statements include the financial results of Anthem Biosciences Limited (Parent Company) and its wholly owned subsidiary of Neoanthem Lifesciences Pvt Ltd.

8. Prior period/year figures have been reclassified wherever required to confirm to the classification of the current period/year.

**For and on behalf of the board of directors of  
Anthem Biosciences Ltd**



**Ajay Bhardwaj**  
Managing Director  
DIN:00333704



Place: Bangalore  
Date: August 13, 2025